New CF Patient Subset For Vertex With Kaftrio's EU Approval
Opportunity Opens Following EU Approval Of Triple Combination
EU approval came quicker than expected for Vertex’s new triple-combination CFTR drug, Kaftrio.
You may also be interested in...
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.